Psoriatic Arthritis
📧 Sign up to get email alerts when something new happens for Psoriatic Arthritis.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2026-06-22Clinical Trial Results: Multicentre ObservatioNal Initiative in Treat to Target Outcomes in Psoriatic Arthritis
Completed multicenter observational study in psoriatic arthritis assessing treat-to-target outcomes; results posted.
-
EMA approval · 2026-06-12EMA Authorised: Fubelv — Biosimilar Collaborations Ireland Limited
EMA has authorised Fubelv as a biosimilar, with indications across various inflammatory arthritis and psoriasis conditions.
-
EMA approval · 2026-06-12EMA Authorised: Apremilast Accord — Accord Healthcare S.L.U.
Accord Healthcare S.L.U. has been authorised in the EU for apremilast (Accord).
-
EMA approval · 2026-06-09EMA Authorised: Rinvoq (upadacitinib) — AbbVie Deutschland GmbH & Co. KG
EU authorization of Rinvoq (upadacitinib) by AbbVie Deutschland for multiple inflammatory indications including rheumatoid arthritis, psoria…
-
EMA approval · 2026-06-05EMA Authorised: Idacio (adalimumab) — Fresenius Kabi Deutschland GmbH
The EMA has authorised Idacio (adalimumab) by Fresenius Kabi Deutschland GmbH for multiple inflammatory diseases, marking a new approved pro…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2026-06-05Clinical Trial Update: A Study to Evaluate the Efficacy and Safety of JNJ-77242113 (Icotrokinra) in Biologic-naïve Participants With Active Psoriatic Arthritis [Phase 3]
A Phase 3 study evaluating the efficacy and safety of JNJ-77242113 (Icotrokinra) in biologic-naïve participants with active psoriatic arthri…
-
CLINICAL_TRIALS trial_result · 2026-06-05Clinical Trial Update: A Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Study Participants With Active Psoriatic Arthritis [Phase 3]
Phase 3 trial evaluating efficacy and safety of bimekizumab in adults with active psoriatic arthritis.
-
CLINICAL_TRIALS trial_result · 2026-06-05Clinical Trial Update: A Long-term Extension Study of Ustekinumab in Pediatric Participants [Phase 3]
Long-term extension study of ustekinumab in pediatric participants (Phase 3) for Crohn disease, ulcerative colitis, and related psoriatic ar…
-
CLINICAL_TRIALS trial_result · 2026-04-29Clinical Trial Update: Evaluation of Sonelokimab in Patients With Active Psoriatic Arthritis Naive to Biologic Disease-Modifying Antirheumatic Drug [Phase 3]
Phase 3 clinical trial evaluating sonelokimab in biologic DMARD–naive patients with active psoriatic arthritis is currently active but not r…
-
EMA approval · 2026-04-24EMA Authorised: Stelara (ustekinumab) — Janssen-Cilag International NV
The EMA has authorised Stelara (ustekinumab) in the EU for psoriasis, psoriatic arthritis, Crohn's disease and ulcerative colitis.
-
CLINICAL_TRIALS research · 2026-04-24Clinical Trial Update: A Study to Evaluate the Effect of Bimekizumab on Gene Expression Biomarkers in Study Participants With Moderate to Severe Plaque Psoriasis [Phase 3]
A Phase 3 clinical trial is evaluating the effect of Bimekizumab on gene expression biomarkers in adults with moderate to severe plaque psor…
-
CLINICAL_TRIALS research · 2026-04-24Clinical Trial Update: A Study to Learn if Bimekizumab Given in Different Ways is Safe and Moves Similarly Throughout the Body Over Time in Adults [Phase 1]
A Phase 1 clinical trial is evaluating the safety and pharmacokinetics of bimekizumab given in different administration methods in adults wi…
-
CLINICAL_TRIALS trial_result · 2026-04-24Clinical Trial Update: A Study to Evaluate the Long-term Safety, Tolerability, and Efficacy of Subcutaneous Sonelokimab in Participants With Psoriatic Arthritis [Phase 3]
A Phase 3 trial update evaluating the long-term safety, tolerability, and efficacy of subcutaneous sonelokimab in people with psoriatic arth…
-
EMA approval · 2026-04-23EMA Authorised: Taltz (ixekizumab) — Eli Lilly and Company (Ireland) Limited
EMA authorised Taltz (ixekizumab) from Eli Lilly for psoriasis, psoriatic arthritis, axial spondyloarthritis, and juvenile idiopathic arthri…
-
EMA approval · 2026-04-23EMA Authorised: Remsima (infliximab) — Celltrion Healthcare Hungary Kft.
EMA authorised Remsima (infliximab) from Celltrion Healthcare Hungary Kft. for multiple inflammatory diseases including rheumatoid arthritis…
-
EMA approval · 2026-04-23EMA Authorised: Amgevita (adalimumab) — Amgen Europe B.V.
EMA has authorised Amgevita (adalimumab) by Amgen Europe B.V., a biosimilar of adalimumab, for multiple inflammatory diseases including rheu…
-
CLINICAL_TRIALS research · 2026-04-22Clinical Trial Update: A Phase II Study to Evaluate the Efficacy and Safety of D-2570 in Subjects With Active Psoriatic Arthritis [Phase 2]
A Phase II clinical trial update indicating that D-2570 is being studied for efficacy and safety in active psoriatic arthritis and is curren…
-
CLINICAL_TRIALS research · 2026-04-22Clinical Trial Update: A Study of SPY072 in Rheumatic Disease [Phase 2]
This clinical trials update outlines a Phase 2 study of SPY072 for rheumatoid arthritis and psoriatic arthritis, with ongoing recruitment an…
-
CLINICAL_TRIALS research · 2026-04-21Clinical Trial Update: Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO [Phase 1]
Phase 1 trial evaluating nivolumab in patients with autoimmune disorders and advanced cancers; the study is currently recruiting.
-
CLINICAL_TRIALS trial_result · 2026-04-20Clinical Trial Update: A Randomized, Double-blind Clinical Trial on the Efficacy of a Dietary Formulation Containing Medium-chain Triglycerides (MCT) and Fiber in Patients With Psoriatic Arthritis [NA]
This entry reports a completed randomized, double-blind trial evaluating a dietary formulation containing medium-chain triglycerides and fib…
-
CLINICAL_TRIALS research · 2026-04-17Clinical Trial Update: Oxidative Stress in Autoimmune Rheumatic Diseases
A University of Thessaly–sponsored clinical trial is recruiting to study oxidative stress in autoimmune rheumatic diseases, including rheuma…
-
EMA approval · 2026-04-16EMA Authorised: Steqeyma (ustekinumab) — Celltrion Healthcare Hungary Kft.
The EMA authorised Steqeyma (ustekinumab) by Celltrion Healthcare Hungary Kft for psoriasis, psoriatic arthritis, and Crohn's disease.
-
EMA approval · 2026-04-16EMA Authorised: Qoyvolma (ustekinumab) — Celltrion Healthcare Hungary Kft.
EMA authorised Qoyvolma (ustekinumab) by Celltrion Healthcare Hungary Kft. for psoriasis, psoriatic arthritis, ulcerative colitis, and Crohn…
-
FDA approval · 2026-04-15FDA Approved: USTEKINUMAB — Supplemental Application (Janssen Biotech, Inc.)
FDA approved a supplemental application for ustekinumab submitted by Janssen Biotech, Inc. The action pertains to a supplemental submission …
-
CLINICAL_TRIALS research · 2026-04-15Clinical Trial Update: Safety and Immunogenicity of the Live Attenuated Tetravalent Butantan-Dengue Vaccine in Autoimmune Rheumatic Diseases [Phase 4]
Phase 4 clinical trial assessing safety and immunogenicity of the live attenuated tetravalent Butantan-Dengue vaccine in autoimmune rheumati…